NEW YORK (GenomeWeb News) — Diamics will supply its molecular-based cancer-diagnostics systems and cervical cancer tools to a Beijing hospital for three years in exchange for at least $22 million, the company said today.
 
Diamics’ C-Map cervical cancer screening system, which is in clinical trials in the US, uses antibodies to identify cell colonies showing dysregulated growth, which could help identify cervical lesions. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.